From insight to innovation: Meeting consumer needs across the weight loss journey

Supplier showcase brought to you by Beneo

10:15 – 10:45 CEST

Speakers:
Silke Ullmann, senior manager nutrition communication, BENEO-Institute
Monica Holmes, marketing intelligence expert, BENEO Marketing
Isabel Trogh, customer technical support manager, BENEO-Technology Center

Synopsis: As the conversation around weight management evolves from calorie reduction to metabolic health and nutrient density, food and supplement manufacturers face new formulation challenges. New consumer research reveals distinct needs across the weight loss journey – from starting GLP-1 medication, to transitioning off it, or pursuing natural weight management. This webinar highlights how these insights translate into product opportunities and shows how low-glycaemic carbohydrate, fibres and protein solutions can support healthy, sustainable outcomes. Discover how BENEO's functional ingredients enable nutrient-dense and metabolic health-supporting concepts that deliver long-term consumer value through science-based innovation.

Beyond GLP-1s: The future of weight management

14 April 2026
11:00 – 12:30 CEST

11:00 - 11:10 CEST
Welcome address:

Kirstin Knight, managing editor, Vitafoods Insights
Francesca Berry, head of content programming, Vitafoods Insights

11:10 – 11:25 CEST
Title: Opportunities from the growth of GLP-1

Speaker:
Mike Hughes, head of research and insight, FMCG Gurus

Synopsis: GLP-1 medication use is on the rise, but the long-term effectiveness of sustained weight loss and reversal of obesity rates remains to be seen. Whilst the market faces opportunities and challenges, wider opportunities exist for the food and drink market beyond catering specifically to the users of medication, such as challenging perceptions around portion control, structured meal-times and differentiating between essential and non-essential eating occasions.

11:25 – 11:40 CEST
Title: What happens after GLP-1s?

Speaker:
Dr Duane Mellor, senior specialist paediatric diabetes dietitian, University Hospitals of Leicester NHS Trust

Synopsis: The introduction of GLP-1s has transformed weight management. It has led to changes in how society sees people living with obesity, it has led to changes in food habits and innovation in food production. There are key questions that need addressing, including how can people reduce risks of regain when discontinuing these drugs? Can we help to make different food choices or behaviours to maintain health gain? Are there any benefits or risks to the wider population of changing our food system to help meet the needs of people taking GLP-1s?

11:40 – 12:30 CEST
Live Q&A with the audience
Got questions? We've got answers! After the presentations, join our interactive Live Q&A to gain deeper insights by connecting with our subject matter experts in real time. This is your opportunity to get answers to your most pressing questions on science, consumer behaviour shifts, or innovations shaping the industry. Be part of the conversation with fellow industry peers to uncover strategies to stay ahead of the curve.

Speakers:
Mike Hughes, head of research & insight, FMCG Gurus
Dr Duane Mellor, senior specialist paediatric diabetes dietitian, University Hospitals of Leicester NHS Trust

Moderator:
Kirstin Knight, managing editor, Vitafoods Insights

Muscle health in the GLP-1 era: A root-cause approach to lean mass preservation

Supplier showcase brought to you by TSI

12:45 – 13:15 CEST

Speaker:
Peter Michael Stone, scientific advisor to TSI Group, TSI Group Co., Ltd

Synopsis: The rapid rise of GLP-1 receptor agonists is reshaping the weight-management landscape and creating new nutritional challenges for consumers. As appetite suppression and rapid weight loss become more common, maintaining lean mass and muscle function has emerged as a critical consideration for long-term health outcomes. This session explores muscle health in the GLP-1 era through a root-cause lens, examining how ageing, hormonal changes, and reduced nutrient intake influence muscle metabolism and body composition. Dr Stone will discuss evidence-based strategies – including nutrition, resistance training, and targeted supplementation – to support lean mass, while highlighting emerging opportunities for brands to develop innovative solutions for the evolving weight-management market.

The GLP-1 landscape: a broader strategy for weight management

Supplier showcase brought to you by Bionap Srl

13:30 – 14:00 CEST

Speaker:
Dr. Vincenzo Zaccaria, head of r&d, Bionap Srl

Synopsis: The rise of GLP-1 medications is reshaping the weight management landscape, expanding consumer expectations beyond weight loss alone. In this webinar, Bionap presents a strategic framework to help brands and formulators address emerging needs with science-backed botanical solutions. ACT EARLY: focuses on botanical support for metabolic balance and healthy weight management before intensive interventions become necessary. SUPPORT WHEN NEEDED: highlights targeted support for digestive comfort, energy, and skin and hair wellness during intensive weight-loss pathways, including GLP-1 use. MAINTAIN FOR LONGER: completes the framework with science-backed support for long-term weight stability and continuity of results.

The collagen breakthrough approach to GLP-1 disruption

Supplier showcase brought to you by Rousselot

14:15 – 14:45 CEST

Speaker:
Florencia Moreno Torres, global marketing manager, Rousselot

Synopsis: Frequent post-meal glucose spikes silently disrupt metabolic health by triggering excessive insulin release, promoting fat storage, and driving cravings and overeating – ultimately affecting vitality and weight management. Nutraceutical solutions that enhance GLP 1 secretion and help stabilise glucose offer a powerful, non-pharmaceutical approach to support energy balance and a healthy weight.

This session will explore key consumer profiles, market opportunities, and application innovations to help brands develop effective, evidence based GLP 1-boosting and glucose support products for healthy consumers seeking natural metabolic and weight management support.

Beyond GLP-1: Clinically Proven Ingredients for Next-Gen Weight Management

Supplier showcase brought to you by Saanroo

15:00 – 15:30 CEST

Speaker:
Mariko Hill, director of scientific affairs - EMEA & APAC, Saanroo

Synopsis: The rapid rise of GLP-1 therapies is reshaping consumer expectations in weight management - but sustainable, accessible nutritional solutions remain essential. This webinar explores how Saanroo's clinically validated branded ingredients can target complementary metabolic pathways beyond GLP-1 stimulation.

We will showcase Trpti® OEA for microbiome and satiety support, Slimaluma® (Caralluma fimbriata) for stress & appetite regulation, and BioBerb® Berberine for blood glucose management. Each ingredient works via distinct mechanisms, offering formulators innovative, evidence-backed strategies to develop next-generation weight management solutions.

Join us to discover the science, applications, and formulation opportunities driving growth in this rapidly evolving category.

Supplement strategies for the realities of GLP-1 weight management

Supplier showcase brought to you by PLT Health Solutions

15:45 – 16:15 CEST

Speakers:
Steve Fink, Vice President of Marketing, PLT Health Solutions
Dr Jeremy Appleton, director of medical & scientific affairs, PLT Health Solutions

Synopsis: The ubiquity of GLP-1 drugs for weight management is changing the landscape of the supplements industry. But the reality of how consumers engage with GLP-1 drugs points to gaps in their promise. The average consumer stops GLP-1 treatment after only six months. Drawbacks include concerns about use of a pharmaceutical, high cost, reduction in lean body muscle mass, and rapid post-use weight gain. These issues present the supplement industry with a variety of opportunities to create products within the GLP-1 universe both during and post-treatment. This webinar will focus on strategies to develop supplement solutions that address muscle mass loss, mobility and post-treatment weight gain related to GLP-1 drugs.